HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ng-Cashin, J. Articles by Serody, J. S. Search for Related Content PubMed PubMed Citation Articles by Ng-Cashin, J. Articles by Serody, J. S.

Host Absence of CCR5 Potentiates Dendritic Cell Vaccination¹

Judith Ng-Cashin^*,,, Jennifer J. Kuhns^,, Susan E. Burkett, John D. Powderly^*,, Robin R. Craven^,, Hank W. van Deventer^*,, Suzanne L. Kirby^*,, and Jonathan S. Serody^2,*,,

Departments of ^* Medicine, Microbiology and Immunology, Lineberger Comprehensive Cancer Center, and Pathology, University of North Carolina School of Medicine, Chapel Hill, NC 27599

Previous work has shown that dendritic cells (DCs) express specific chemokine receptors that allow for coordinated movement in vivo. To test the in vivo relevance of this, we used a murine melanoma system and knockout mice to investigate the function of the chemokine receptor CCR5 and its ligands, CCR ligand (CCL)3 and CCL5. We found that the lack of CCR5 in the host mouse resulted in delayed tumor growth, but this effect was overcome at a higher tumor load. With the administration of tumor charged DCs, CCR5^-/- mice that had previously been injected with tumor were completely protected from tumor. This effect was dependent on the dose of tumor cells and the expression of CCR5 on the DC and its absence in the host. In contrast, the loss of the CCR5 ligand, CCL3, led to an early delay in tumor growth that did not persist, while the absence of the CCR5 ligand, CCL5, had no effect. Blocking the activity of CCR5 in the host may represent a new strategy for enhancing the activity of a therapeutic melanoma DC vaccine.

This article has been cited by other articles:

				C. L. Thio, J. Astemborski, A. Bashirova, T. Mosbruger, S. Greer, M. D. Witt, J. J. Goedert, M. Hilgartner, A. Majeske, S. J. O'Brien, et al. Genetic Protection against Hepatitis B Virus Conferred by CCR5{Delta}32: Evidence that CCR5 Contributes to Viral Persistence J. Virol., January 15, 2007; 81(2): 441 - 445. [Abstract] [Full Text] [PDF]

				C. A. Wysocki, Q. Jiang, A. Panoskaltsis-Mortari, P. A. Taylor, K. P. McKinnon, L. Su, B. R. Blazar, and J. S. Serody Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease Blood, November 1, 2005; 106(9): 3300 - 3307. [Abstract] [Full Text] [PDF]

				H. W. van Deventer, W. O'Connor Jr., W. J. Brickey, R. M. Aris, J. P.Y. Ting, and J. S. Serody C-C Chemokine Receptor 5 on Stromal Cells Promotes Pulmonary Metastasis Cancer Res., April 15, 2005; 65(8): 3374 - 3379. [Abstract] [Full Text] [PDF]

				G. C. Hildebrandt, K. M. Olkiewicz, S. Choi, L. A. Corrion, S. G. Clouthier, C. Liu, J. S. Serody, and K. R. Cooke Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation Blood, March 15, 2005; 105(6): 2249 - 2257. [Abstract] [Full Text] [PDF]